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S
everal operational definitions for sarcopenia have recently been proposed. [1] [2] [3] [4] [5] [6] [7] Conceived initially as the loss of lean body mass accompanying aging, 8 early operational definitions of sarcopenia were based solely on appendicular lean mass (ALM) from dual-energy X-ray absorptiometry (DXA) standardized to height, 9 but the relationship between muscle or lean mass and functional decline and disability is uncertain. [10] [11] [12] [13] [14] [15] [16] Thus, more recently proposed consensus definitions of sarcopenia have broadened the criteria for diagnosis to include components of strength and physical performance. The predictive validity of these more-recent definitions has not been established.
Before sarcopenia is defined as a clinical syndrome, a biomarker, a risk factor, or an outcome in clinical trials, its utility should be evaluated. To establish the utility of a novel measure, several conditions must be met. First, the measure must increase the likelihood of development of other adverse outcomes, independent of age and potentially other known clinical factors (e.g., body mass index (BMI)). Second, the measure should improve ability to discriminate individuals who go on to develop outcomes from those who do not. Third, the measure should appropriately and significantly reclassify people in terms of risk of development of adverse outcomes.
Therefore, the associations between five definitions of sarcopenia were evaluated 1,2,5-7,9,17 using four adverse outcomes (recurrent falls, hip fractures, functional limitations, mortality). The discriminative ability and reclassification of the definitions for likelihood of these outcomes were also determined. Analyses were completed in the Osteoporotic Fractures in Men (MrOS) Study, a prospective cohort of community-dwelling older men.
METHODS

Study Population
From 2000 to 2002, 5,994 ambulatory communitydwelling men aged 65 and older without bilateral hip replacement were enrolled in MrOS, a multicenter cohort study of aging and osteoporosis. 18, 19 All men provided written informed consent, and the institutional review board at each center approved the study.
Clinical Measurements
Weight was measured using a balance beam or digital scale and height using wall-mounted stadiometers. BMI was calculated as weight (kg)/height 2 (m 2
. ALM and total hip bone mineral density (BMD) were assessed using DXA (Hologic 4500, Waltham, MA) as previously described. 20 Gait speed was measured over a 6-m course, using the average of two trials (m/s). 21 Grip strength (kg) from two tests of each hand was assessed using Jamar handheld dynamometers; the maximum value obtained on all tests was analyzed. Ability and time to complete five repeated chair stands was assessed. Men self-reported a physician's diagnosis of a number of medical conditions (Table 2 footnote); the number of these conditions was summed. Participants also self-reported activity level (Physical Activity Scale for the Elderly), 22 race, alcohol use, smoking status, health status (excellent, good vs fair, poor, very poor), and history of fracture before the baseline visit.
Sarcopenia Definitions
Published operational definitions for sarcopenia include Baumgartner's; 9 Newman's; 17 the International Working (Table 1) . The ESPEN and SCWD recommendations were similar to those of the EWGSOP and IWG, respectively, and therefore were not analyzed separately. The consensus definitions are similar in that all combine lean mass assessed using DXA with a strength or physical performance component; the Newman and Baumgartner definitions rely on lean mass estimates alone. The definitions also overlap to some extent. For lean mass, the EWGSOP and IWG definitions used the Baumgartner criteria as the lean mass component, and the EWGSOP and FNIH definitions define slowness as gait speed of 0.8 m/s or less.
Outcomes
Men answered mailed questionnaires about falls and fractures three times per year; response to these questionnaires exceeded 99%. When a participant did not return a questionnaire in a timely fashion, clinic staff contacted him or his next of kin. Men who reported two or more falls in the year after baseline were considered recurrent fallers, and those who reported no or one fall were not considered recurrent fallers. Fractures and deaths were centrally adjudicated using physician review of radiology reports, death certificates, and hospital discharge summaries when available. Men were queried about self-reported functional limitation (inability to walk 2-3 blocks, climb 10 steps without resting, prepare meals, shop, or do heavy housework) at baseline and the second clinic visit questionnaire 4.6 years later.
Statistical Analyses
Of the 5,994 men at baseline, 60 were missing gait speed, grip strength, or lean mass data, leaving 5,934 eligible for inclusion in follow-up analyses. Analysis of each outcome included a different number of participants; 106 men were missing follow-up data for recurrent falls, leaving 5,828 in analyses; all 5,934 men had follow-up data for hip fracture; 1,200 men were classified as having a functional limitation at baseline, 19 were missing this data at baseline, and 989 were missing follow-up data for functional limitations at Visit 2 (including those who died or terminated before the visit), leaving 3,726 in the functional limitations analyses; and 65 were missing final adjudication of vital status (because of a missing or pending collection of death certificate), leaving 5,869 men in mortality analyses.
Characteristics of participants were compared according to presence or absence of each sarcopenia definition using t-tests, Wilcoxon tests, and chi-square tests as appropriate.
Proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for hip fracture and mortality, and the proportionality assumption was tested and was not found to be violated. Logistic regression models were used to estimate odds ratios (ORs) and 95% CIs for recurrent falls and functional limitations. All models were age adjusted; hip fracture models were also adjusted for femoral neck BMD.
To quantify the discriminative ability of each sarcopenia definition for the study outcomes, the area under the receiver operating characteristic curve (AUC) was calculated from logistic models and the analogous Harrell C-statistic 23 from proportional hazards models. The AUC or C-statistic was calculated in the reference models and in models that additionally included the sarcopenia definition. The difference and 95% CI in the AUC or C-statistic and between these two models were calculated. Reference models for falls, functional limitations, and mortality included age alone; for hip fractures, the reference model included age and BMD.
The net reclassification improvement (NRI) statistic was used to quantify the amount of reclassification attributable to addition of each sarcopenia definition to the reference model. 24 A no-category approach to calculating the NRI was used, because established risk thresholds for study outcomes are not widely used in clinical settings. Risk estimates were calculated as the predicted probability of the event from logistic regression models or 1 minus the survivor function estimate from proportional hazard models. For example, for mortality, two proportions were determined for those who died: the proportion for whom addition of the sarcopenia definition to the referent model increased predicted probability (representing appropriate reclassification) and the proportion for whom addition of the sarcopenia definition to the referent model decreased their risk estimate (representing inappropriate reclassification). To ensure that small changes in predicted probability between the old and new models was not driving the NRI values, each individual's predicted probability must have changed by at least 1%; otherwise their predicted probability change was considered to be 0. The proportion that was inappropriately reclassified was then subtracted from the proportion that was appropriately reclassified, resulting in the net reclassification of those who died. For those who did not die, the proportion with appropriate reclassification (the proportion whose risk estimates decreased with the addition of the sarcopenia definition to the reference model) was also calculated, and the proportion with inappropriate reclassification (the proportion whose risk estimate increased with the addition of the sarcopenia definition to the reference model) was subtracted from this, resulting in the net reclassification of those who did not die. To calculate the overall NRI, the net reclassification values for those who died were then added to the reclassification values for those who did not die. The overall NRI ranges from -2 to 2, with negative values indicating inappropriate reclassification and positive values indicating appropriate reclassification. CIs were calculated from standard errors described previously. 24 Analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Cary, NC) or Stata version 12.1 (Stata Corp, College Station, TX).
RESULTS
The prevalence of sarcopenia was low to moderate overall ( Table 1) . Characteristics of participants according to the Table 2 . In general, those classified as having sarcopenia (according to any definition) were older and weaker and had lower lean mass, more comorbid conditions, worse self-rated health, lower activity level, and lower BMD than those classified as not having sarcopenia. Associations between sarcopenia classification and smoking, alcohol use, BMI, and history of fracture varied according to the definition used.
Six hundred ninety-four men (11.9%) were classified as recurrent fallers in the year after the baseline examination. Neither the Baumgartner nor Newman definition was associated with recurrent falls. The likelihood of recurrent falls was two to three times as great in men with sarcopenia according to definitions that incorporated weakness or slowness as in men without sarcopenia, but the FNIH Definition 2 did not reach statistical significance, perhaps because so few met the definition (Figure 1) . Overall, when compared with the reference model with age alone, differences in the AUCs with the addition of each sarcopenia definition that included slowness or weakness mirrored the significance of the associations (the ORs) but tended to be small in absolute magnitude, with the greatest difference in the AUC of only 0.01 (for the IWG definition). For all sarcopenia definitions that included weakness or slowness, the NRI showed better reclassification for men without an event (0.03 to 0.35), but there was also substantial reclassification in the inappropriate direction for those with events (-0.05 to -0.33), resulting in no overall reclassification improvement (-0.05 to 0.01) ( Table 3 ). The Baumgartner and Newman definitions appropriately reclassified events but inappropriately reclassified nonevents, resulting in no change in the overall NRI.
During follow-up (9.8 AE 3.0 years), 207 men (3.5%) experienced a hip fracture. There was no association between sarcopenia (IWG, EWGSOP, Newman, or Baumgartner) or "weakness and low lean mass" according to the FNIH (Definition 1) and hip fracture risk (Figure 1 ). The risk of hip fracture was four times as great in men with "slowness with weakness and low lean mass" according to the FNIH (Definition #2) as in those without, although the CIs were wide. The addition of none of the sarcopenia definitions to the reference model with age and BMD resulted in significant changes in the C-statistic. None of the sarcopenia definitions significantly improved the reclassification of participants over the reference model (overall NRI -0.06 to 0.01, P > .05 for all) ( Table 3) .
During follow-up (4.6 AE 0.4 years), 590 (15.8%) men had a new functional limitation. Men who met the Newman, IWG, or EWGSOP definition had a greater likelihood of functional limitation. There was no association between the Baumgartner definition or the FNIH "weakness and low lean mass" definition (Definition 1) and development of a functional limitation. The association between the FNIH definition "slowness with weakness and low lean mass" (Definition 2) and functional limitation could not be estimated because only one of the participants in this subset (those free of functional limitations at baseline) met the criteria for FNIH Definition 2.
During follow-up (9.8 AE 3.0 years), 2,003 men (34.1%) died. Men who met any definition of sarcopenia had a greater risk of mortality than those without these conditions (Figure 1) . Changes in the C-statistic with the addition of all sarcopenia definitions to the reference model with age alone were statistically significant but small (0.001 to 0.004, P < .05 for all).For sarcopenia definitions that included a weakness or slowness component, the NRI showed better reclassification for men without an event (0.05 to 0.26), but frequent reclassification in the inappropriate direction for those with events (0.18 to 0.41) resulted in overall reclassification in the inappropriate direction (-0.07 to -0.16) ( Table 3 ). The Baumgartner and Newman definitions that include lean mass alone demonstrated significant overall reclassification in the appropriate direction (0.20 and 0.15) for mortality. This reclassification was primarily due to correct reclassification of a large number of men without events (0.40 and 0.38) that inappropriate reclassification in nonevents partly offset (-0.20 and -0.23).
The FNIH alternative definitions were evaluated (Table 4 ) and did not materially change estimates for falls, hip fracture, functional limitations, and mortality from those determined using the primary FNIH definitions. Neither of the FNIH alternative summary definitions significantly changed the AUC from that of the reference model, with the exception of the alternative Definition 1 and a small change in the C-statistic for mortality. In addition, overall NRI for these outcomes was not significant or was in the inappropriate direction.
DISCUSSION
These results suggest that these proposed definitions of sarcopenia as currently constructed would be of limited clinical utility in healthy community-dwelling men. Despite differences between the definitions in cut-points for gait speed, grip strength, and lean mass, the risk estimates for falls, fracture, and mortality increased and were fairly similar across the definitions. The proposed sarcopenia definitions do not appear to materially change discrimination based on AUC and C-statistic analyses for falls, hip fracture, functional limitations, or mortality from that of simple models. Overall, only the Baumgartner and Newman definitions significantly improved reclassification in the appropriate direction for mortality; none of the other definitions significantly reclassified men in the expected direction in terms of risk of recurrent falls, hip fractures, functional limitations, or mortality from simple models.
One challenge for evaluating usefulness of a definition of sarcopenia is that selection of the outcome against which to evaluate candidate definitions is not obvious. It is likely that age-related decline in muscle function is related to various outcomes including falls, fractures, functional limitation, hospitalization, disability, and mortality. For example, physical performance, particularly slow gait speed, is related to falls, hip fracture, disability, and mortality. 21, [25] [26] [27] [28] Thus, no single outcome can serve as a criterion standard against which to evaluate potential clinical definitions of sarcopenia. A few reports have evaluated individual consensus definitions against single outcomes such as mortality [29] [30] [31] but have not undertaken more-complete analyses comparing the predictive validity of multiple proposed definitions of sarcopenia with the risk of several adverse outcomes simultaneously, as was done in the current study. Recurrent falls over 1 year With event, n = 694 Appropriately reclassified, n (%)
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687 (18) 646 (17) 393 (10) 420 (11) 45 (1) 103 ( There were no incident functional limitations in men who met the FNIH Definition 2, so these models could not be run. NRI = net reclassification improvement; CI = confidence interval. Recent analyses have supported an association between the FNIH components (the low lean mass criterion using ALM and BMI and the weakness criterion) or the composite definition with disability, limitations in walking, and poor physical performance in older adults, [32] [33] [34] although these reports did not evaluate discrimination or reclassification of the FNIH sarcopenia definition or its components. One report in older adults in Hong Kong found that none of several sarcopenia definitions considered predicted incident physical limitations and that AUCs for the various definitions were similarly low. 35 With regard to hip fracture, the current study found that the C-statistic for a simple model with age and BMD alone was 0.806 and that none of the sarcopenia definitions significantly improved the C-statistic from that of this simple model. The discriminative ability of the FRAX algorithm 36 for fracture risk has been previously evaluated in MrOS; the AUCs in those models that accounted for the competing risk of mortality were 0.77 for the FRAX algorithm that included BMD and 0.69 for the FRAX algorithm that did not include BMD. 37 It was initially postulated that a clinical diagnosis of sarcopenia would identify those at high risk of these adverse outcomes, because poor physical performance and strength (and to a lesser extent low lean mass) have been previously associated with falls, hip fractures, disability, and mortality, 21, 25, 27, 28 but the results do not support this hypothesis. There are several possible reasons for these findings. First, the proposed operational definitions may not correctly identify the underlying condition. Refinement of the definition of sarcopenia, with omission of some criteria and addition of others, may more accurately identify those at risk. For example, although slow gait speed appears to increase the risk of many health outcomes, 26, 28 alternative measures, such as inability to rise from chair, may better stratify those at risk of poor outcomes. Previous analyses in MrOS found that men unable to rise from a risk of hip fracture was eight times as great as that of men with the fastest (best) performance on the repeat chair stand test. 21 However, the reclassification and discriminative ability of chair rise performance for the outcomes examined in the present analyses have not been evaluated. Similarly, although assessment of grip strength is highly reproducible 38 and is associated with falls, hip fractures, disability, and mortality, 21, 25, 39, 40 it is possible that lower extremity strength is a more clinically relevant measure in terms of risk stratification. Nevertheless, lower extremity strength is more difficult to measure accurately in a clinical setting than is grip strength. Also, muscle power includes strength and velocity; alternative definitions of sarcopenia with a criterion based on power may improve discriminative ability, but again, measures of lower extremity power are difficult to assess in clinical settings. In addition, lean mass according to DXA is only a surrogate measure of muscle mass, 41 and more-direct and -precise assessment of muscle mass could lead to different results. In addition, aside from the Newman definition, none of the sarcopenia definitions take into account fat mass. Criteria that include the relative amount of lean mass to fat mass, as well as physical function, have not been developed and may provide better predictive validity than current measures that do not account for fat. Another possibility is that sarcopenia, as currently conceptualized, is nota true clinical syndrome, in that the presence of this condition does not increase the risk of subsequent poor outcomes regardless of the operational definition used.
MrOS is a large, well-characterized cohort with little loss to follow-up and excellent assessment of endpoints, although a few limitations must be noted. First, the MrOS cohort was relatively healthy, well functioning, and overweight and had a low prevalence of sarcopenia at baseline, especially for the definitions of sarcopenia that include low lean mass and a functional component. The results of these analyses may differ in a less-healthy population with a higher prevalence of sarcopenia or with higher or lower body weight, although if these definitions of sarcopenia are found to be more discriminative in terms of risk of poor outcomes in less-healthy populations, such evidence would not necessarily support the use of the definitions in a general clinic population. Second, the MrOS cohort is all male and mostly white. Therefore, extrapolation of these results to other groups may not be warranted. Separate criteria for sarcopenia for nonwhite individuals have been suggested, for example for Asians, 42 but these criteria are not data driven, and the predictive and discriminative ability of these race-specific criteria have not been evaluated. Further evaluation or development of sarcopenia definitions in nonwhite populations is warranted. Third, MrOS data were included in the pooled analyses that were used, in part, to develop the FNIH sarcopenia definitions. Thus, it was initially expected that the FNIH definitions (and their alternatives) might perform better (in terms of discrimination and reclassification) than the other definitions that did not directly employ MrOS data in their construction, but none of the definitions of sarcopenia performed well, so inclusion of the MrOS data in the previous analyses was unlikely to influence the conclusions. Fourth, sarcopenia measures from only a single visit were evaluated. The extent to which sarcopenia status changes over time and whether fluctuating sarcopenia status confers risk of clinical outcomes has not been determined. Finally, the use of the NRI to evaluate a new marker has been criticized for several reasons, 43, 44 mostly notably because the NRI statistic does not weigh the importance of reclassification based on clinical consequences; that is, the importance of reclassification of individuals with events is given equal weight to reclassification in those without events. Nevertheless, even when the data are interpreted without the calculation of the overall NRI, the conclusions are unchanged. The goal of adding new information about sarcopenia to a clinical assessment is to better identify those at risk of poor outcomes, rather than excluding those at lower risk. In this study, adding information about sarcopenia resulted in lower estimated risk of the outcome in those who went on to have an event, which would result in correctly identifying fewer, not more, men at risk of adverse outcomes. Thus, even without relying on the overall NRI, the sarcopenia definitions do not help identify men who are at risk of adverse outcomes.
Although sarcopenia according to any of the definitions used was associated with greater likelihood of recurrent falls and greater risk of mortality (and less consistently associated with risk of hip fracture and functional limitation), the definitions do not improve on age alone in terms of discrimination and reclassification of risk of important adverse outcomes in community-dwelling older men. Thus, in their current state, these definitions are unlikely to be clinically useful in a general population of older men. Before any sarcopenia definition is implemented in clinical practice, it should be shown to be useful in predicting geriatric outcomes of interest and providing good discrimination and reclassification of risk of these outcomes. Future studies should investigate the utility of these criteria in populations at higher risk of adverse outcomes.
